Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, New York 10019-6064
July 20, 2015
Via EDGAR
Mr. Ronald E. Alper
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
vTv Therapeutics Inc.
Amendment No. 3 to Registration Statement on Form S-1
Filed July 13, 2015
File No. 333-204951
Ladies and Gentlemen:
On behalf of our client, vTv Therapeutics Inc., a Delaware corporation (the “Company”), we hereby submit in electronic form the accompanying Amendment No. 4 (“Amendment No. 4”) to the Registration Statement on Form S-1 of the Company (the “Registration Statement”), marked to indicate changes from Amendment No. 3 to the Registration Statement filed with the Securities and Exchange Commission (the “Commission”) on July 13, 2015.
Amendment No. 4 reflects the inclusion of a preliminary price range for the Company’s Class A common stock, certain information previously left blank in the Registration Statement that is derived from such price range, pro forma financial information as well as certain additional changes.
* * * *
If you have any questions concerning the above, please do not hesitate to contact either the undersigned at (212) 373-3052 or David E. Sobel at (212) 373-3226.
Sincerely,
/s/ Lawrence G. Wee
Lawrence G. Wee, Esq.
cc: | Stephen L. Holcombe |
vTv Therapeutics Inc. | |
Marc D. Jaffe, Esq. | |
Senet S. Bischoff, Esq. | |
Latham & Watkins LLP |